Abstract
Treatment resistance in schizophrenia (TRS) is a major clinical problem with 20-35% of psychotic patients showing non-response to standard antipsychotic treatment. Neuromelanin-sensitive MRI sequence (NM-MR), which indirectly measures dopamine synthesis in the substantia nigra (SN), has potential as biomarker for TRS, since TRS patients have lower dopamine synthesis than treatment responders with positron emission tomography imaging. NM-MRI indeed shows increased signal in schizophrenia patients, but has not yet been tested in TRS.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
